| Market Cap | 36.26M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -22.29M | Forward P/E | 6.78 | EPS next Y | 51.20% | 50D Avg Chg | -1.00% |
| Sales | 58.65M | PEG | -0.04 | EPS past 5Y | 43.93% | 200D Avg Chg | -10.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | 15.00% | 52W High Chg | -34.00% |
| Recommedations | - | Quick Ratio | 0.89 | Shares Outstanding | 9.47M | 52W Low Chg | 51.00% |
| Insider Own | 19.68% | ROA | -9.64% | Shares Float | 95.90M | Beta | 1.22 |
| Inst Own | 23.83% | ROE | - | Shares Shorted/Prior | 89.70K/16K | Price | 0.95 |
| Gross Margin | 34.28% | Profit Margin | -38.01% | Avg. Volume | 53,479 | Target Price | - |
| Oper. Margin | -10.52% | Earnings Date | Aug 2 | Volume | 24,623 | Change | -4.14% |
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
